Trial Profile
Examining the Efficacy of a Therapeutic Combination of Dronabinol (Synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide for Tourette Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Dronabinol (Primary) ; Dronabinol/palmitoylethanolamide (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Proof of concept; Therapeutic Use
- 18 Oct 2021 According to a SciSparc media release, data from this study were published in The Journal of Neuropsychiatry and Clinical Neurosciences.
- 18 Oct 2021 Results published in the Media Release
- 21 Aug 2019 Status changed from recruiting to completed.